This week's top news stories and latest developments
?? Trending news from the industry
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies.
Radioligand Therapy (RLT) is a promising approach in the treatment of various cancers, including those that are resistant to chemotherapy as well as in patients who have not undergone prior cancer treatment.
Lidia Pieri earned a Master’s degree with honours in high energy physics at CERN, a PhD in theoretical astroparticle physics from Rome-3 (Italy) and an Executive MBA in Business Innovation with honours from the MIB school in Trieste.
Scientists at the?University of Pittsburgh?have elucidated why metastatic uveal melanoma, a rare and aggressive cancer, is resistant to conventional immunotherapies, as well as how adoptive therapy can successfully treat it.
They have also explained the development of a new clinical tool that predicts which patients will respond to adoptive therapy. The work, supported by?UPMC Enterprises, will aid the improvement of personalised therapies.
Researchers at the University of Oklahoma collaborated with the Johns Hopkins School of Medicine, the University of Texas Health Science Centre and Yale School of Medicine, to elucidate the previously unknown mechanisms that cause the onset of cancer cachexia.
World-first research from the University of South Australia shows that drug-loaded 3D printed films could alter cancer treatments forever. The novel films were shown to kill over 80 percent of liver cancer cells and significantly reduce recurrence rates while minimising systematic toxicities of traditional chemotherapy.
?? What to watch
Carleton Sage , PhD, DiscoveryAI Business Line Leader, will discuss the integration of AI/ML approaches into the drug discovery process from hit ID through lead optimisation. Specific applications of AI-based ADME model development approaches used in the development of SAFIRE will be discussed.
?? Date: 26 June
? Time: 16:00 BST
领英推荐
Join us for this webinar as we explore the role of organoids in advancing treatment of neurological disorders.
Expert M Angeles Rabadan, Ph.D. , Founder and Chief Executive Officer, will explore the latest breakthroughs in organoid technology and their application in early drug discovery for neurological conditions.
?? Date: 29 May
? Time: 15:00 BST
Join the webinar with Eurofins DiscoverX to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
?? Date: 15 May
? Time: 16:00 BST
?? What to read
Download this exclusive report to discover key immuno-oncology advancements and breakthroughs including targets playing crucial roles in multiple tumour survival pathways, how to improve the analysis of single-cell transcriptomic data and a new wave of promising NK cell therapeutics.
What to listen to ??
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology. This conversation features Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, and Roy Baynes, Chief Scientific Officer at Eikon Therapeutics.?
Sign up for free! ???
Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.
Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.